1. Merck & Eisai Hit Major Setback as Keytruda-Lenvima Combo Fails Late-Stage Kidney Cancer Trial
A high-stakes late-stage clinical trial for a promising kidney cancer treatment has failed, delivering a significant blow to the development programs of pharmaceutical giants Merck and Eisai. The Phase 3 LEAP-003 trial, which was testing a combination of Merck's blockbuster immunotherapy Keytruda (pembrolizumab) and Ei...